Neovasc Inc. (NVCN)
After hours:
| Previous close | 29.36 |
| Open | 29.28 |
| Bid | 29.41 x 800 |
| Ask | 29.75 x 800 |
| Day's range | 29.28 - 29.75 |
| 52-week range | 4.59 - 29.88 |
| Volume | |
| Avg. volume | 63,218 |
| Market cap | 82.372M |
| Beta (5Y monthly) | 2.01 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -12.40 |
| Earnings date | 10 May 2023 - 15 May 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 24.00 |
- Simply Wall St.
Neovasc's (TSE:NVCN) investors will be pleased with their solid 171% return over the last year
The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. On the other hand, if you...
- GlobeNewswire
Neovasc Shareholders Approve Acquisition by Shockwave Medical
VANCOUVER, BC, March 06, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ: NVCN)(TSX: NVCN), a leader in the development of minimally invasive devices for the treatment of refractory angina, is pleased to announce that its Shareholders (as defined below) have approved the previously-announced acquisition of all of the outstanding common shares of the Company (the “Shares”) by Shockwave Medical, Inc. (“Shockwave”) by way of a statutory plan of arrangem
- GlobeNewswire
Neovasc Announces German Reimbursement Renewal
VANCOUVER and MINNEAPOLIS, Feb. 01, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Neovasc, Inc. (“Neovasc” or “the Company”) (NASDAQ , TSX : NVCN) today announced the German Institute for the Hospital Remuneration System (“InEK”) has awarded the Neovasc Reducer™ (“Reducer”), a CE-Marked medical device for the treatment of refractory angina, NUB Status 1 designation for 2023. New examination and treatment methods (NUBs) are comprised of novel and innovative medicines, medical products and procedure
